Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

pharmafile | June 19, 2020 | News story | Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq 


Genentech and Roche have released new Phase 3 on the efficacy of their immunotheraoy drug Tecentriq (atezolizumab), when used in combination with Abraxane chemotherapy followed by doxorubicin and cyclophosphamide, in the treatment of early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.

The new data revealed that, after 21 weeks of treatment, patients receiving Tecentriq prior to surgery were less likely to display evidence of detectable tumour tissue at the time of surgery regardless of their PD-L1 expression compared to those receiving the placebo combo.

According to the findings, Tecentriq generated a “statistically significant and clinically meaningful improvement in pathological complete response (pCR)”, as measured on the American Joint Committee on Cancer (AJCC) staging system, compared to placebo plus chemo.

Tecentriq was also tested for secondary endpoints including benefit in overall survival, disease-free survival and quality of life, but specific details in these measures were not revealed. Roche and Genentech instead confirmed that full results would be presented at an upcoming medical event.

“Triple-negative breast cancer remains an aggressive disease with high rates of recurrence,” commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development. “Our goal in treating TNBC at its earliest stages is to provide people with the best chance for a future cure. Adding Tecentriq to chemotherapy now has the potential to help women with TNBC at multiple different stages of the disease.”

Matt Fellows


Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Roche to acquire Carmot Therapeutics for $2.7bn

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, …


Genentech and NVIDIA enter AI research collaboration

Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA …

Latest content